The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999
Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter 40:59-60, , 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
New Antiepileptic Drugs
Arch Neurol 55:1181-1183, Bourgeois,B.F.D., 1998
New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994
Epilepsy: New Advances
Lancet 385:884-898, Moshe, S.L.,et al, 2015
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Postmarketing Modifications in the Safety Labeling of the New Antiepileptics
Neurol 68:1536-1537, Buck,M.L.,et al, 2007
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
JAMA 293:557-564,615, Chang,S.M.,et al, 2005
Monotherapy in Epilepsy
Arch Neurol 61:1361-1365, Vazquez,B., 2004
Recent Advnaces in the Treatment of Epilepsy
Arch Neurol 60:929-935, Nguyen,D.K. &Spencer,S.S., 2003
Therapy for the Epilepsies
Arch Neurol 59:732-735, Van Ness,P.C., 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Evolving Treatment Strategies for Epilepsy
JAMA 287:2917-2920, Diaz-Arrastia,R.,et al, 2002
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Do New Antiepileptic Drugs Justify Their Expense
Arch Neurol 55:1140-1142, Chadwick,D., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
Assessment of Vagus Nerve Stimulation for Epilepsy
Neurol 49:293-297, Fisher,R.S.,et al, 1997
Surgery for Seizures
NEJM 334:647-652, Engel,J.Jr., 1996
The Use of Parenteral Antiepileptic Drugs & The Role of Fosphenytoin
(Suppl Editor) , Neurol 46:S1-S2896., Wilder,B.J., 1996
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
New Antiepileptic Drugs
Neurol 44:787-795, Harden,C.L., 1994
General AI May Revolutionize Neurology 0 Or It Might be Bad
JAMA Neurol doi 10.1001/JAMANEUROL.2025.0905, Westover,M.B. & Westover,A.M., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Educational Strategies for Clinical Supervision of Artificial Intelligence Use
NEJM 393:786-797, Abdulnour,R-E. E.,et al, 2025
AI in Neurology: Everything, Everywhere, all at One PRT 2:Speech, Sentience, Scruples, and Service
Ann Neurol 98:431-447, Rizzo, M., 2025
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023
NEjM 388:1201-1208,1220, Haug,C.H. & Drazen,J.M., 2023
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine
NEJM 388:1233-1239, Lee,P., et al, 2023
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023
Large Language Models in Neurology Research and Future Practice
Neurol 101:1058-1067, Romano,M.F.,et al, 2023
Lentiviral Haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
Lancet 399:372-383, Fumagalli, F.,et al, 2022
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Stroke After Transcatheter Aortic Valve Replacement
JAMA 321:2287-2289, Messe, S.R. & Ailawadi, G., 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019